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Heat-shock protein 70 (Hsp70) is frequently found on the plasma membrane of a large 
number of malignant tumors including non-small cell lung cancer (NSCLC) and gets 
released into the blood circulation in lipid vesicles. On the one hand, a membrane (m)
Hsp70-positive phenotype correlates with a high aggressiveness of the tumor; on the other 
hand, mHsp70 serves as a target for natural killer (NK) cells that had been pre-stimulated 
with Hsp70-peptide TKD plus low-dose interleukin-2 (TKD/IL-2). Following activation, 
NK cells show an up-regulated expression of activatory C-type lectin receptors, such 
as CD94/NKG2C, NKG2D, and natural cytotoxicity receptors (NCRs; NKp44, NKp46, 
and NKp30) and thereby gain the capacity to kill mHsp70-positive tumor cells. With 
respect to these results, the efficacy of ex vivo TKD/IL-2 stimulated, autologous NK cells 
is currently tested in a proof-of-concept phase II clinical trial in patients with squamous 
cell NSCLC after radiochemotherapy (RCT) at the TUM. Inclusion criteria are histolog-
ical proven, non-resectable NSCLC in stage IIIA/IIIB, clinical responses to RCT and a 
mHsp70-positive tumor phenotype. The mHsp70 status is determined in the serum of 
patients using the lipHsp70 ELISA test, which enables the quantification of liposomal and 
free Hsp70. Squamous cell and adeno NSCLC patients had significantly higher serum 
Hsp70 levels than healthy controls. A significant correlation of serum Hsp70 levels with 
the gross tumor volume was shown for adeno and squamous cell NSCLC. However, 
significantly elevated ratios of activated CD69+/CD94+ NK cells that are associated with 
low serum Hsp70 levels were observed only in patients with squamous cell lung cancer. 
These data might provide a first hint that squamous cell NSCLC is more immunogenic 
than adeno NSCLC.
Keywords: biomarker, tumor markers, biological, heat-shock protein 70, nsclc, gross tumor volume, 
lymphocytes, immune responses
TaBle 2 | Patient collective #2.
number
Gender Female 8
Male 47
Histology Squamous cell 28
Adeno 24
Large cell 1
Other 1
No histology 1
UICC stage Ia 1
Ib 0
IIa 2
IIb 0
IIIa 18
IIIb 34
IV 0
Clinico-pathological characteristics of 55 NSCLC patients treated at the Martin-Luther 
University Hospital, Halle-Wittenberg.
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inTrODUcTiOn
According to recent statistics, lung cancer is still among the most 
frequent causes of cancer-related deaths and the second most 
common cancer in both men and women in Western societies 
(1). The numbers of new cases are further increasing especially in 
Asia and Africa (2). According to the GLOBOCAN report 2000 
(3), the incidence of lung cancer worldwide is 1,238,900 with a 
mortality of 1,103,100 and a 5-year prevalence of 1,394,400. One 
reason for this high mortality is that patients with lung cancer 
are frequently diagnosed in advanced tumor stages since the 
symptoms, such as dyspnea, coughing, or chest pain, are quite 
unspecific for a long period of time (4). Even after radical sur-
gery, chemo-, and/or radiotherapy using up-to-date therapeutic 
approaches could not improve the outcome of locally advanced 
tumor stages. The progression-free and overall survival of non-
small cell lung cancer (NSCLC) patients in stage IIIA and IIB is 
often <16 months (5). Therefore, there is a high medical need to 
explore new treatment modalities to increase life expectancy and 
to develop minimal invasive methods for an earlier detection of 
NSCLC.
In 2013, immunotherapy was elected as the “breakthrough of 
the year” for the treatment of cancer by the journal “Science” (6). 
The basis for this was the increase in knowledge in the detec-
tion of tumor-specific traits that have the potential to serve as 
tumor-specific targets for immunotherapeutic approaches. 
Along this line, our laboratory investigated the potential of the 
major stress-inducible heat-shock protein 70 (Hsp70, HSPA1A) 
as a tumor-specific target. Hsp70 is frequently overexpressed in 
many different tumor types like hematological malignancies, 
breast, prostate, colon, brain, and lung cancer (7, 8). Hsp70 assists 
protein folding, prevents protein aggregation and apoptotic cell 
death under physiological conditions and following stress (9, 
10). Tumor cells compared to normal cells not only express 
significantly higher levels of Hsp70 in the cytosol (7, 8), but also 
exhibit an unusual plasma membrane localization of Hsp70 (11). 
Therefore, mHsp70 has the potential as a tumor-specific target 
for immunological approaches. Additionally, we have shown 
recently that mHsp70 positive tumor cells actively secrete Hsp70 
in lipid vesicles, most likely exosomes, that mirror the membrane 
orientation of the cell from which they are derived (12). Based on 
these findings, liposomal Hsp70 which is found in the peripheral 
blood circulation can reflect the mHsp70 status of the tumor. 
We have established the lipHsp70 ELISA (13), which enables the 
detection of Hsp70 in the serum and plasma of patients. The use 
of the monoclonal antibody (mAb) cmHsp70.1 (14, 15) in this 
ELISA allows a quantitative determination of free and liposomal 
Hsp70 in the blood, whereas other commercially available Hsp70 
ELISA tests only detect free Hsp70.
A mHsp70-positive tumor phenotype exerts dual functions, 
on the one hand, a high mHsp70 density is associated with a high 
aggressiveness of the tumor (16) and the potential of metastatic 
spread; on the other hand, mHsp70 on tumor cells serves as a 
target for activated natural killer (NK) cells, which have been 
incubated either with Hsp70 protein or TKD a 14mer peptide 
derived from Hsp70 in combination with low-dose IL-2 (TKD/
IL-2) (12, 17, 18). Following activation, these NK cells regain the 
capacity to kill mHsp70-positive tumor cells in  vitro (19) and 
in vivo (15, 20) via granzyme B-mediated apoptosis (21).
For a better understanding of this duality of mHsp70, we 
addressed the question whether serum Hsp70 levels are associ-
ated with clinical parameters, such as gross tumor volume (GTV) 
at diagnosis and after radiochemotherapy (RCT), and whether 
serum Hsp70 levels can have impact on the immune phenotype 
of squamous cell and adeno NSCLC (18).
MaTerials anD MeThODs
Patient Material
Blood samples of healthy human donors and NSCLC patients of 
the Klinikum rechts der Isar, TUM (patient collective #1; Table 1) 
and the Martin Luther University Hospital Halle-Wittenberg 
(patient collective #2, Table 2) were collected between 2008 and 
2015. In patient collective #1, blood was taken from patients with 
squamous cell (n = 25) and adenocarcinoma (n = 18) of the lung 
at diagnosis and directly after RCT (n = 6), and from age- and 
gender-matched healthy human volunteers (n = 126) as a control 
group. Tumor biopsies were obtained from nine NSCLC patients, 
six in stage IV, and three in stage 3 (patient collective #1). The 
TaBle 1 | Patient collective #1.
number
Gender Female 11
Male 32
Histology Squamous cell 25
Adeno 18
UICC stage Ia 1
Ib 1
IIa 0
IIb 0
IIIa 13
IIIb 13
IV 15
Clinico-pathological characteristics of 43 NSCLC patients treated at the Klinikum rechts 
der Isar, TU München, Munich, Germany.
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median age of all patients of patient collective #1 was 64 years and 
ranged from 23 to 95 years. In a screening study, NSCLC patients 
are stratified for their tumor stage and Hsp70 phenotype to enter 
a phase II clinical trial at the TUM, which is entitled “Targeted NK 
cell based adoptive immunotherapy for the treatment of patients 
with NSCLC after radiochemotherapy (RCT)” (18). In patient col-
lective #2, blood was taken from 55 patients (median age 63 years, 
range 47–86 years) with advanced stage, inoperable NSCLC with 
an indication for primary RCT. These patients were recruited into 
a pilot study entitled “Potential plasma hypoxia markers in the 
radiotherapy of non-small cell lung cancer” (22). Characteristics 
of both patient collectives are summarized in Tables  1 and 2. 
Briefly, blood was collected in two EDTA KE/9 ml tubes and one 
Serum Z/9 ml separator tube (S-Monovette, Sarstedt, Nümbrecht, 
Germany). For the serum, blood was allowed to clot for 15 min at 
room temperature. After collecting 1.4 ml of EDTA blood for flow 
cytometry, plasma and serum were obtained by centrifugation at 
750 g for 10 min. Aliquots of 100–300 μl were stored at −80°C for 
further analysis. The studies were approved by the local Ethics 
Committee of the Medical Faculties of both Universities (TUM, 
Halle-Wittenberg) and written informed consent was obtained 
from all patients before entering the trial. All procedures were 
performed in accordance to the Declaration of Helsinki, 1975, as 
revised in 2008. Clinical stage was determined according to the 
UICC TNM classification, seventh edition.
radiochemotherapy and Volumetric 
Parameters
Three-dimensional conformal RT (3D-RT) was given normofrac-
tionated (5 fractions/week) with curative intent (66 Gy total dose, 
2  Gy single dose; Siemens Primus, Germany). Chemotherapy 
consisted of cisplatin (20 mg/m2 body surface on days 1–5) and 
vinorelbine (25 mg/m2 body surface on day 1) in treatment week 
1 and 5 (2 courses). RT was CT based (Siemens Lightspeed RT, 
Germany) and all patients received a PET-scan (Philips Accel, 
USA) before RT. CT and PET images were merged and GTV 
was defined as the primary tumor and involved nodes (patho-
logic confirmed, highly suspicious by CT and PET). GTV was 
delineated by an experienced radiation oncologist at planning 
CT before RT and all image data were registered in the Oncentra 
Masterplan external beam planning software (Nucletron, USA) 
used for RT plan calculation.
Detection of hsp70 in serum/Plasma 
Using the liphsp70 elisa
The Hsp70 content in the blood of NSCLC patients and healthy 
donors was determined using the lipHsp70 ELISA, which is 
equally suitable for serum and plasma samples (13). Using the 
monoclonal cmHsp70.1 antibody as a detection reagent (15), it 
is possible to detect both, soluble-free and lipid-bound Hsp70 
in the serum/plasma of patients and healthy human individuals. 
This ELISA allows a quantitative analysis of the total amount of 
Hsp70 in the circulation blood (13). Briefly, 96-well MaxiSorp 
Nunc-Immuno plates (Thermo, Rochester, NY, USA) were coated 
overnight with 2  μg/ml rabbit polyclonal antibody (Davids, 
Biotechnologie, Regensburg, Germany), directed against human 
Hsp70 in sodium carbonate buffer (0.1  M sodium carbonate, 
0.1 M sodium hydrogen carbonate, pH 9.6). After washing three 
times with phosphate-buffered saline (PBS, Life Technologies, 
Carlsbad, CA, USA) with 0.05% Tween-20 (Calbiochem, Merck, 
Darmstadt, Germany), wells were blocked with 2% milk pow-
der (Carl Roth, Karlsruhe, Germany) in PBS for 1.5 h at 27°C. 
Following another washing step, serum samples diluted 1:5 in 
CrossDown Buffer (AppliChem, Chicago, IL, USA) were added 
to the wells for 2 h at 27°C. Then, the wells were washed again 
and incubated with 4  μg/ml of the biotinylated mouse mAb 
cmHsp70.1 (multimmune, Munich, Germany) in 2% milk 
powder in PBS for 2  h at 27°C. Finally, after another washing 
step, 0.2 μg/ml horseradish peroxidase-conjugated streptavidin 
(Pierce, Thermo, Rockford, IL, USA) in 1% bovine serum albu-
min (Sigma-Aldrich, St. Louis, MO, USA) was added for 1 h at 
27°C. Binding was quantified by adding substrate reagent (R&D 
Systems, Minneapolis, MN, USA) for 30 min at 27°C and absorb-
ance was read at 450  nm, corrected by absorbance at 570  nm, 
in a Microplate Reader (BioTek, Winooski, VT, USA). An eight-
point standard curve was determined for each ELISA test using 
0–50  ng/ml recombinant Hsp70 diluted in CrossDown Buffer. 
Each sample was measured in triplicates.
immunohistochemical staining
Immunohistochemical staining was performed on formalin-
fixed and paraffin-embedded specimen of lung tumors (n = 9). 
Sections were cut, dewaxed and hydrated, heated for 30  min 
in a microwave oven in 600  ml DAKO retrieval buffer, then 
washed for 5  min in H2O. After washing twice with T-PBS 
buffer, specimens were blocked for 1 h in 10% rabbit serum in 
PBS containing 1% BSA. Immunohistochemistry was done with 
streptavidine–biotin complex (StreptABC) using mouse mAb 
cmHsp70.1 (multimmune, Munich Germany) at a dilution of 
1:200 overnight 2 h at 4°C.
analysis of the lymphocyte 
subpopulations with Flow cytometry
In order to determine the proportion of different lymphocyte 
subpopulations, flow cytometric (FACS) analysis was performed 
using freshly collected EDTA blood (1.4  ml). Therefore, blood 
(100 μl) was transferred into 14 test tubes and then fluorescently 
labeled antibodies were added. The antibody combinations that 
were used for the FACS analysis are summarized in Table  3. 
After an incubation time of 15 min in the dark, the tubes were 
centrifuged for 5 min at 500 g at room temperature after adding 
2 ml of PBS/10% FCS washing buffer. In order to eliminate eryth-
rocytes, cells were incubated with lysing buffer (1:9 dilution of BD 
Lysing Solution Cat. 3490202 with millipore H2O) for 10 min at 
the room temperature in the dark. The respective percentages of 
B, T, and NK cell subpopulations are defined as the proportion 
of cells within the lymphocyte gate R1 (see Figure  3). For the 
determination of regulatory T cells, buffer A (1:10 dilution of 
component A with H2O) was added to the respective tubes. After 
two washing steps, cells were permeabilized with buffer C (1:50 
dilution of buffer A with component B) for 30 min in the dark. 
Following another two washing steps, a PE-conjugated antibody 
TaBle 3 | Panel of antibodies and 14 antibody combinations used in the study.
specificity antibody clone company cat no. Volume
Ctrl IgG1-FITC X40 BD 345815 5
IgG1-PE X40 BD 345816 5
IgG1-PerCP X40 BD 345817 5
IgG1-APC X40 Caltag/Invitrogen MG 105 1
T/NK CD94-FITC HP-3D9 BD 555888 5
CD56-PE NCAM16.2 BD 345811 5
CD3-PerCP SK7 BD 345766 10
CD45-APC HI30 Caltag/Invitrogen MHCD 4505 1
B/T/NK CD56-FITC NCAM16.2 BD 345811 5
CD19-PE HIB19 BD 555413 20
CD3-PerCP SK7 BD 345766 10
CD45-APC HI30 Caltag/Invitrogen MHCD 4505 1
T/NK CD56-FITC NCAM16.2 BD 345811 5
CD16-PE 3G8 BD 555407 10
CD3-PerCP SK7 BD 345766 10
CD45-APC HI30 Caltag/Invitrogen MHCD 4505 1
T/NK CD56-FITC NCAM16.2 BD 555518 5
NKG2D-PE 149810 R&D FAB139P 10
CD3-PerCP SK7 BD 345766 10
CD69-APC L78 BD 340560 5
T/NK CD56-FITC NCAM16.2 BD 345811 5
NKp30-PE IM3709 BC PN 3709 10
CD3-PerCP SK7 BD 345766 10
CD69-APC L78 BD 340560 5
T/NK CD56-FITC NCAM16.2 BD 345811 5
NKp46-PE IM3711 BC PN 3711 10
CD3-PerCP SK7 BD 345766 10
CD69-APC L78 BD 340560 5
T/NK CD94-FITC HP-3D9 BD 555888 5
NKG2D-PE 149810 R&D FAB139P 10
CD3-PerCP SK7 BD 345766 10
CD56-APC B159 BD 555518 10
T/NK CD94-FITC HP-3D9 BD 555888 5
NKp30-PE IM3709 BC PN 3709 10
CD3-PerCP SK7 BD 345766 10
CD56-APC B159 BD 555518 10
T/NK CD94-FITC HP-3D9 BD 555888 5
NKp46-PE IM3711 BC PN 3711 10
CD3-PerCP SK7 BD 345766 10
CD56-APC B159 BD 555518 10
CD4/CD8 T CD4-FITC RPA-T4 BD 555346 20
CD8-PE RPA-T8 BD 555366 20
CD3-PerCP SK7 BD 345766 10
CD45-APC HI30 Caltag/Invitrogen MHCD 4505 1
Ctrl IgG1-FITC X40 BD 345815 5
IgG1-PE X40 BD 345816 5
IgG1-PerCP X40 BD 345817 5
IgG1-APC X40 Caltag/Invitrogen MG 105 1
CD4 Treg CD4-PE RPA-T4 BD 555346 20
FoxP3-FITC 259/C7 BD 560046 20
CD3-PerCP SK7 BD 345766 10
CD25-APC 2A3 BD 340907 5
CD8 Treg CD8-PE RPA-T8 BD 555366 20
FoxP3-FITC 259/C7 BD 560046 20
CD3-PerCP SK7 BD 345766 10
CD25-APC 2A3 BD 340907 5
APC, allophycocyanin; B, B lymphocyte; BD, Becton Dickinson Biosciences; BC, Beckman Coulter; CD, cluster of differentiation; COPD, chronic obstructive pulmonary disease;  
Ctrl, control; FITC, fluorescein isothiocyanate; NK, natural killer cell; PE, phycoerythrin; T, T lymphocyte; Treg, regulatory T cells.
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directed against the intracellular transcription factor forkhead 
box P3 (FoxP3) was added for another 30  min. After another 
two washing steps, 5 × 104 cells were analyzed on a FACScalibur 
instrument (Becton Dickinson, Heidelberg, Germany).
statistical analysis
Statistical analysis was performed using the IBM SPSS 20.0 
software package for windows (SPSS Inc., USA). Statistically 
significant differences between Hsp70 levels of patients with high 
and low GTV and high and low CD94 expression, lymphocyte 
subpopulations of healthy donors, patients with squamous cell 
and adenocarcinoma as well as between the percentage of all lym-
phocytes of patients with high and low Hsp70 expression were 
determined with Mann–Whitney’s U-test. Correlation between 
serum Hsp70 levels and GTV was evaluated using Spearman’s 
Rank Correlation Coefficient. Potential differences in Hsp70 
serum levels in NSCLC patients before and after RCT were 
determined with the Wilcoxon Rank-Sum Test. Comparison 
of Hsp70 levels in the serum of two patient groups (squamous 
cell and adeno NSCLC) and a group of healthy donors was also 
performed using the Kruskal–Wallis test with a Dunn multiple 
comparison test. A value of p < 0.05 was considered as statisti-
cally significant.
resUlTs
comparison of hsp70 levels in Patients 
with squamous cell, adeno nsclc, and 
healthy human individuals
Serum samples derived from 25 squamous cell and 18 adeno 
NSCLC patients (patient collective #1), and 126 age- and gender-
matched healthy donors were analyzed to determine the Hsp70 
levels in the peripheral blood. As shown in Figure 1A, patients 
with squamous cell and adeno NSCLC (NSCLC; n =  43) have 
significantly higher serum Hsp70 levels (p ≤ 0.001) compared to 
healthy control controls (healthy; n = 126), as determined with 
the lipHsp70 ELISA, at diagnosis. The mean serum Hsp70 levels 
of patients with squamous cell and adeno NSCLC, 16.69 ± 2.7 ng/
ml and 14.51 ± 2.49 (median 12.15 vs. 12.20 ng/ml), respectively, 
did not differ significantly from each other (p = 0.825), but both 
tumor types differed significantly (p ≤ 0.001) from that of healthy 
controls (7.0  ng/ml) as shown in Figure  1B. A representative 
image of an Hsp70 positive tumor section of a squamous cell 
(upper graph) and an adeno (lower graph) NSCLC in stage IV 
is illustrated in Figure  1C. All nine tumor sections of NSCLC 
patients (six in stage IV and three in stage III) had elevated Hsp70 
serum levels and exhibited a strong Hsp70 staining in the tumor 
cells but not in the connective tissue. Studies are ongoing that aim 
to analyze a potential correlation between cytosolic and serum 
Hsp70 levels in a larger panel of patients.
To investigate whether RCT impacts on serum Hsp70 levels in 
a small subgroup of patients (n = 6), blood was collected before 
start of therapy and directly after completion of therapy. Although 
Hsp70 levels after RCT remained significantly higher compared 
to those of healthy human individuals, a slight drop, which did 
not reach statistical significance (p = 0.463; Wilcoxon Rank-Sum 
Test), was detectable in the serum Hsp70 levels after completion 
of RCT (Figure 1D).
correlation of hsp70 levels at Diagnosis 
with Tumor Volume in nsclc Patients
A comparison of free and lipid-bound Hsp70 in the circula-
tion of tumor patients revealed that a major part of Hsp70 is 
bound to lipid vesicles, most likely exosomes, which are actively 
secreted by viable tumor cells carrying Hsp70 on their cell 
surface (12, 23). Therefore, we studied a potential correlation 
of the detected serum Hsp70 levels with the GTV of 55 NSCLC 
patients (patient collective #2; Table  2) that was determined 
by PET-imaging before start of RCT. The average tumor size 
of these patients was 219.9 ±  32.3  ml and the mean Hsp70 
level was 11.2 ± 1.7 ng/ml. The Spearman’s Rank Correlation 
Coefficient revealed a significant correlation (p = 0.03) between 
these two metric parameters. Regarding the median GTV of 
143.6 ml, these patients were subdivided into a group with low 
(≤143.6 ml) and high (>143.6 ml) median GTV. As shown in 
Figure  2, patients in the high GTV group had significantly 
higher serum Hsp70 levels than patients with a low tumor 
volume (p < 0.05).
Differences in the immune Phenotype of 
healthy human Donors, Patients with 
squamous cell and adenocarcinoma of 
the lung
Nowadays, it is well accepted that an intact immune system plays 
a key role in long-term tumor control and in prevention of distant 
metastasis (24). Therefore, we comparatively investigated differ-
ences in the relative amount of lymphocytes and lymphocyte 
subpopulations, such as B, T, and NK cells, in the EDTA blood 
of healthy human donors (n = 10) and NSCLC patients (patient 
collective #1; n =  43; Table 1) at diagnosis, using multi-color 
FACS analysis. The panel of fluorescence-labeled antibodies and 
antibody combinations that were used in the study, is summa-
rized in Table 3. Compared to blood of healthy human donors, 
the relative number of lymphocytes was significantly lower in 
patients with squamous cell (n = 25; p = 0.001) and adeno (n = 18; 
p = 0.008) NSCLC, although the percentage of lymphocytes in 
patients with different histology was very similar (22.4 ± 1.6% for 
squamous cell and 21.8 ± 2.4% for adenocarcinoma patients vs. 
34.5 ± 1.77% in healthy controls) (Figure 3). The gating strategy 
of the lymphocytes is exemplified in the lower part of Figure 3. 
Gate R1 refers to the gated population of lymphocytes, whereas 
gate R2 represents granulocytes. The population of CD14+ mono-
cytes is localized between the gates R1 and R2.
With respect to CD19+ B cells, patients with squamous 
cell carcinoma had significantly lower percentages of B cells 
than healthy donors (p =  0.001) and adenocarcinoma patients 
(p = 0.02) (Figure 4A). A comparison of different CD3+ T cell 
subpopulations, such as CD4+, CD8+, CD4+/CD25+ regulatory, 
NKG2D+, and CD94+ T cells revealed no major differences, apart 
from a significant increase in the subpopulation of CD3+/CD56+ 
NKT cells in patients with adeno lung carcinomas compared to 
healthy controls (p = 0.038) (Figure 4B). The activation marker 
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that patients with squamous cell NSCLC had elevated ratios of 
CD3−/CD56+ NK cells and CD3−/NKG2D+ NK cells in general, 
compared to healthy controls (p = 0.053) and adenocarcinoma 
patients (Figure 4C).
correlation of hsp70 serum levels with 
lymphocyte subpopulations in squamous 
cell and adenocarcinoma Patients
CD3−/CD94+ NK cells were found to be significantly elevated in 
squamous cell carcinoma of the lung (Figure 4C). Furthermore, 
we have shown earlier that the C-type lectin receptor CD94 
plays a key role in the recognition of Hsp70 by NK cells (17). To 
investigate the influence of serum Hsp70 on the ratio of CD3−/
CD94+ NK cells, patients with squamous cell (n  =  25) and 
adenocarcinoma (n =  18) were divided into groups with high 
(≥8.5% in squamous cell and ≥6.5% in adenocarcinoma) and 
low (<8.5% in squamous cell and <6.5% in adenocarcinoma) 
median percentages of CD3−/CD94+ NK cells. It appeared that 
patients with squamous cell NSCLC with a high CD3−/CD94+ 
NK cell ratio had significantly lower serum Hsp70 levels than 
the corresponding group with a low ratio of CD3−/CD94+ NK 
cell ratio (p = 0.048) (Figure 5A). The CD94+ NK cell popula-
tion was also found to be positive for CD69, which indicates 
that these NK cells are active. Patients with high percentages of 
CD94+/CD69+ NK cells have low Hsp70 serum levels and also a 
lower GTV, which indicates that these NK cells might be able to 
control the growth of mHsp70-positive tumor cells. In contrast, 
patients with adenocarcinoma showed no significant differences 
with respect to the ratio of CD3−/CD94+ NK cells and serum 
FigUre 1 | hsp70 serum levels (nanogram per milliliter) in healthy human individuals and patients with squamous cell and adeno nsclc at 
diagnosis and directly after rcT therapy. (a) Serum Hsp70 levels of healthy donors (healthy; n = 126; median Hsp70 level: 7.03 ng/ml, 95th percentile: 
13.84 ng/ml) and NSCLC patients (NSCLC; n = 43; median Hsp70 level: 12.15 ng/ml, 95th percentile = 40.20 ng/ml) (patient collective #1) at diagnosis measured 
with the lipHsp70 ELISA; ***p < 0.001 (Mann–Whitney U-Test). (B) Serum Hsp70 levels of healthy donors (healthy; n = 126) and patients with squamous cell 
(squamous; n = 25; median Hsp70 level: 12.10 ng/ml; 95th percentile: 40.50 ng/ml) and adeno (adeno; n = 18; median Hsp70 level: 12.38 ng/ml; 95th percentile: 
40.20 ng/ml) NSCLC (patient collective #1) at diagnosis measured with the lipHsp70 ELISA; ***p < 0.001 (Kruskal–Wallis test with Dunn’s multiple comparison test). 
(c) Representative immunohistochemical images of a squamous cell and adeno NSCLC section stained with cmHsp70.1 antibody; 20× magnification (patient 
collective #1). The upper graph shows a squamous cell NSCLC and the lower graph an adeno NSCLC section. Only the tumor tissue but not the surrounding tissue 
shows an Hsp70 staining. (D) Serum Hsp70 levels of NSCLC patients (n = 6; patient collective #1) at diagnosis (before) and directly after RCT (after).
CD69 appeared to be slightly, but not significantly, elevated on 
CD3+ T cells of patients with squamous cell (p = 0.81) and adeno-
carcinoma (p =  0.197) patients compared to healthy controls 
(Figure 4B). A representative picture of the strategy to analyze 
CD3+/CD4+ T cells is illustrated in the inset of Figure  4B. In 
contrast to the T cell subpopulations, significant differences were 
observed with respect to CD3− NK cell subpopulations regard-
ing the activation marker CD69 and the C-type lectin receptor 
CD94. Patients with squamous cell NSCLC had significantly 
higher percentages of CD3−/CD56+/CD69+ (p  =  0.016) and 
CD3−/CD56+/CD94+ (p = 0.028) NK cells than healthy controls 
(Figure 4C). Although not significantly different, it also appeared 
FigUre 2 | hsp70 serum levels and gross tumor volume (gTV) in 
nsclc patients. According to their median Hsp70 levels, NSCLC patients 
(n = 55; patient collective #2) were divided into patients with low GTV 
(≤143.6 ml; median GTV: 109.40 ml; 95th percentile: 296.30 ml) and high 
GTV (>143.6 ml; median GTV: 163.50 ml; 95th percentile: 688.00 ml); 
*p < 0.05 (Mann–Whitney U-test).
FigUre 3 | relative amounts of lymphocytes (%) in healthy human 
individuals and patients with squamous cell and adeno nsclc. 
Comparison of the percentage of peripheral blood lymphocytes (PBL) in 
healthy human individuals (n = 10) and patients with squamous cell (n = 25) 
and adeno (n = 18) NSCLC at diagnosis (patient collective #1); **p < 0.01, 
***p < 0.001 (Mann–Whitney U-test). Graph below: gate R1 refers to the 
population of PBL which is analyzed by FACS, G2 refers to the population of 
granulocytes.
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that patients with squamous cell NSCLC had elevated ratios of 
CD3−/CD56+ NK cells and CD3−/NKG2D+ NK cells in general, 
compared to healthy controls (p = 0.053) and adenocarcinoma 
patients (Figure 4C).
correlation of hsp70 serum levels with 
lymphocyte subpopulations in squamous 
cell and adenocarcinoma Patients
CD3−/CD94+ NK cells were found to be significantly elevated in 
squamous cell carcinoma of the lung (Figure 4C). Furthermore, 
we have shown earlier that the C-type lectin receptor CD94 
plays a key role in the recognition of Hsp70 by NK cells (17). To 
investigate the influence of serum Hsp70 on the ratio of CD3−/
CD94+ NK cells, patients with squamous cell (n  =  25) and 
adenocarcinoma (n =  18) were divided into groups with high 
(≥8.5% in squamous cell and ≥6.5% in adenocarcinoma) and 
low (<8.5% in squamous cell and <6.5% in adenocarcinoma) 
median percentages of CD3−/CD94+ NK cells. It appeared that 
patients with squamous cell NSCLC with a high CD3−/CD94+ 
NK cell ratio had significantly lower serum Hsp70 levels than 
the corresponding group with a low ratio of CD3−/CD94+ NK 
cell ratio (p = 0.048) (Figure 5A). The CD94+ NK cell popula-
tion was also found to be positive for CD69, which indicates 
that these NK cells are active. Patients with high percentages of 
CD94+/CD69+ NK cells have low Hsp70 serum levels and also a 
lower GTV, which indicates that these NK cells might be able to 
control the growth of mHsp70-positive tumor cells. In contrast, 
patients with adenocarcinoma showed no significant differences 
with respect to the ratio of CD3−/CD94+ NK cells and serum 
FigUre 1 | hsp70 serum levels (nanogram per milliliter) in healthy human individuals and patients with squamous cell and adeno nsclc at 
diagnosis and directly after rcT therapy. (a) Serum Hsp70 levels of healthy donors (healthy; n = 126; median Hsp70 level: 7.03 ng/ml, 95th percentile: 
13.84 ng/ml) and NSCLC patients (NSCLC; n = 43; median Hsp70 level: 12.15 ng/ml, 95th percentile = 40.20 ng/ml) (patient collective #1) at diagnosis measured 
with the lipHsp70 ELISA; ***p < 0.001 (Mann–Whitney U-Test). (B) Serum Hsp70 levels of healthy donors (healthy; n = 126) and patients with squamous cell 
(squamous; n = 25; median Hsp70 level: 12.10 ng/ml; 95th percentile: 40.50 ng/ml) and adeno (adeno; n = 18; median Hsp70 level: 12.38 ng/ml; 95th percentile: 
40.20 ng/ml) NSCLC (patient collective #1) at diagnosis measured with the lipHsp70 ELISA; ***p < 0.001 (Kruskal–Wallis test with Dunn’s multiple comparison test). 
(c) Representative immunohistochemical images of a squamous cell and adeno NSCLC section stained with cmHsp70.1 antibody; 20× magnification (patient 
collective #1). The upper graph shows a squamous cell NSCLC and the lower graph an adeno NSCLC section. Only the tumor tissue but not the surrounding tissue 
shows an Hsp70 staining. (D) Serum Hsp70 levels of NSCLC patients (n = 6; patient collective #1) at diagnosis (before) and directly after RCT (after).
Hsp70 levels (p  =  0.908) (Figure  5B). These findings might 
indicate that squamous cell NSCLC is more immunogenic than 
adeno NSCLC.
DiscUssiOn
Many lung tumors are diagnosed at advanced stages, which often 
restrict curative-intent treatment. In bronchial carcinoma, first 
diagnosis can be delayed by unspecific symptoms like coughing 
or dyspnea, which is also seen in inflammatory diseases of the 
lung, such as chronic obstructive pulmonary disease (COPD) or 
pneumonia. Apart from that, the majority of patients with the 
diagnosis COPD are smokers who additionally have an increased 
risk of developing lung cancer. Consequently, there is an urgent 
need for novel tumor biomarkers that can distinguish malignant 
from benign diseases. In contrast to normal cells, tumor cells 
frequently present Hsp70 on their surface. Membrane Hsp70-
positive tumor cells have the capacity to actively secrete Hsp70 
in lipid vesicles with molecular characteristics of exosomes (8, 
9, 12). In a large variety of different malignant tumor entities, 
FigUre 4 | comparison of the immune phenotype of squamous cell and adeno nsclc patients with healthy donors. (a) Relative amount of B cells in 
the blood of healthy donors (n = 10), squamous cell (n = 25) and adeno (n = 18) NSCLC patients, as determined by FACS analysis (patient collective #1); *p < 0.05, 
***p = 0.001 (Mann–Whitney U-test). (B) Percentage of T cell subpopulations in the blood of healthy donors (n = 10), squamous cell (n = 25) and adeno (n = 18) 
NSCLC patients (patient collective #1); *p < 0.05 (Mann–Whitney U-test). A representative example of the analysis of CD3+/CD4+ helper T cells by FACS analysis is 
shown in the inset (percentages of positively stained cells are shown in each quadrant of the dot blot). (c) Percentage of NK cell subpopulations in the blood of 
healthy donors (n = 10), squamous cell (n = 25) and adeno (n = 18) NSCLC patients (patient collective #1); *p < 0.05 (Mann–Whitney U-test).
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elevated Hsp70 levels in the serum could be detected (4, 5) which 
reflect a mHsp70-positive tumor phenotype. Herein, we could 
show significantly elevated levels of Hsp70 in the peripheral blood 
circulation of patients with squamous cell and adeno NSCLC 
when compared to healthy individuals. Previous work of our 
group has demonstrated that differences exist in Hsp70 serum 
levels in patients with inflammatory diseases, such as chronic 
hepatitis or liver cirrhosis and tumors, such as hepatocellular 
carcinoma (HCC) (25). All patients exhibited elevated Hsp70 
levels in the serum compared to healthy controls, but the highest 
Hsp70 levels were detected in the group of tumor patients. In 
line with these findings, it has been demonstrated that NSCLC 
patients have higher Hsp70 levels in the blood than patients with 
COPD (26). These findings might provide a first hint that Hsp70 
could have the potential as a tumor-specific biomarker, which is 
able to distinguish inflammatory and tumor diseases.
Since liposomal Hsp70, which can be quantified in the serum 
and plasma of patients, is derived from viable tumor cells (13, 
27), we were interested to study the impact of RCT on serum 
Hsp70 levels in a small cohort of six NSCLC patients diagnosed 
with NSCLC stage IIIA and IIIB from whom blood was taken at 
diagnosis and after RCT. Despite a slight drop directly after com-
pletion of RCT, serum Hsp70 levels remained significantly higher 
than those in healthy individuals. This means that it might be 
possible to determine the Hsp70 tumor phenotype in the serum 
of patients not only at diagnosis but also during RCT.
Tumor staging in the follow-up period (2–3 months after RCT) 
revealed clinical responses, such as partial response or stable 
disease in these patients. Future studies on a larger patient cohort 
will elucidate whether clinical responses can be determined by a 
drop in the serum Hsp70 levels since the major part of circulating 
Hsp70 is actively released in a lipid-bound form by viable tumor 
cells (13). In order to further test this hypothesis, the GTV was 
compared to the serum Hsp70 levels. Herein, we could show that 
a small GTV was associated with low Hsp70 and a large GTV with 
high serum Hsp70 levels in NSCLC patients (n = 55; collective 
#2). Furthermore, a significant correlation between serum Hsp70 
levels and PET-based GTV was shown using Spearman’s Rank 
Order Correlation. A potential correlation of the Hsp70 levels 
with the UICC stage has to be performed in a patient cohort with 
a more balanced distribution of different UICC stages. Studies 
of Zimmermann et  al. (26) have shown that the Hsp27 and 
Hsp70 serum levels could discriminate clinical stages in NSCLC 
and the group of Bauer et  al. (28) has shown that the tumoral 
expression of both HSPs might provide useful biomarkers for risk 
stratification of UICC stage I/II colon cancer. Considering the 
potential prognostic and predictive quality of tumor volume and 
its changes during RT of cancer (29, 30), serial GTV registrations 
at different time points before, during and after RT by CT, MRI, 
or PET will be determined together with serum Hsp70 levels in 
ongoing studies.
Nevertheless, further research is necessary to assess in more 
detail how homogeneously membrane Hsp70 is expressed in 
tumor cells within one tumor or in tumors of different patients 
in order to validate a direct correlation between serum Hsp70 
levels and the viable tumor mass. Immunohistochemistry data 
reveal that tumor cells, but not the surrounding normal tissue, 
are Hsp70 positive. Equally important is to determine which 
factors can influence the active secretion of Hsp70-containing 
vesicles by tumor cells. In the tissue of patients with squamous 
cell carcinoma of the head and neck, a high membrane Hsp70 
expression on viable tumor cells was found to be associated with 
high serum Hsp70 levels (31). Salamuta S. Mambula observed a 
re-binding of extracellular Hsp70 to the cell surface of prostate 
FigUre 5 | comparison of the cD94 immune phenotype and hsp70 
serum levels in squamous cell and adeno nsclc patients.  
(a) Correlation of the CD94 expression and serum Hsp70 levels in squamous 
cell NSCLC patients (n = 25) (patient collective #1). NSCLC patients were 
divided in a group with low (≤8.5% CD3−/CD94+ NK cells; median Hsp70 
level: 17.45 ng/ml; 95th percentile: 59.00 ng/ml) and high (>8.5% CD3−/
CD94+ NK cells; median Hsp70 level: 10.45 ng/ml; 95th percentile: 17.70 ng/
ml) percentage of CD3−/CD94+ NK cells; *p < 0.05 (Mann–Whitney U-test). 
(B) Correlation of the CD94 expression and serum Hsp70 levels in adeno 
NSCLC patients (n = 18) (patient collective #1). NSCLC patients were divided 
in a group with low (≤6.5% CD3−/CD94+ NK cells; median Hsp70 level: 
12.15 ng/ml; 95th percentile: 40.20 ng/ml) and high (>6.5% CD3−/CD94+ NK 
cells; median Hsp70 level: 12.35 ng/ml; 95th percentile: 22.50 ng/ml) 
percentage of CD3−/CD94+ NK cells; *p < 0.05 (Mann–Whitney U-test).
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carcinoma cells after its release (32). This phenomenon might 
also have an impact on circulating levels of Hsp70.
Apart from the fact that high membrane Hsp70 expression 
levels are associated with and aggressive tumor phenotype, 
radioresistance (16), and tumor progression (33), Hsp70 can also 
provide a target for the innate immune system (11, 34, 35). In gen-
eral, the immune system of each individual human blood donor 
is highly individual, depending on the genetic constitution com-
bined with the exposition to various antigens during life. Patients 
with solid tumors often show an immunosuppressed immune 
phenotype due to a variety of tumor immune escape mechanisms 
(36). In the present study, we intended to detect differences in the 
immune phenotype of patients with NSCLC of different histol-
ogy and healthy human individuals. Considering that patients 
with squamous cell and adenocarcinoma had significantly lower 
percentages of lymphocytes in the peripheral blood than healthy 
controls (Figure 4A), our findings confirm that the immune sys-
tem is essential for tumor control. Since membrane Hsp70 acts 
as a recognition structure for Hsp70-peptide pre-activated NK 
cells (35), we asked the question whether lipid-bound, circulat-
ing Hsp70 has an impact on the immune phenotype of peripheral 
blood lymphocytes (PBL). Flow cytometric analysis of the blood 
of patients with squamous cell carcinoma showed decreased 
percentages of B cells but elevated percentages of activated NK 
cell subpopulations in patients with squamous cell, but not adeno 
NSCLC. Significantly increased percentages of CD69+/CD94+ 
NK cells were found in these patients compared to the healthy 
donors and adenocarcinoma patients. We could show that high 
serum Hsp70 levels are associated with a larger GTV in squamous 
cell but not adeno NSCLC. Regarding Figures  5A,B, patients 
with a lower percentage of CD94+/CD69+ activated NK cells have 
higher Hsp70 serum levels in squamous cell NSCLC. Since high 
Hsp70 serum levels are associated with a larger GTV we specu-
late that CD94+/CD69+ activated NK might be able to control 
growth of membrane Hsp70-positive tumor cells. Depending on 
its subcellular localization Hsp70 exerts dual functions. On the 
one hand, high intracellular and membrane-bound Hsp70 levels 
protect tumor cells from apoptotic cell death and thus mediate 
therapy resistance; on the other hand, membrane Hsp70 acts as 
a recognition structure for activated NK cells. Highly malignant 
tumor cells that secrete large amounts of Hsp70 might escape 
protective antitumor immunity by inducing tolerance, and 
therefore high Hsp70 levels that are associated with a larger 
GTV might be associated with a suppression of C-type lectin-
positive NK cells. Vice versa, high percentages of CD94+/CD69+ 
NK cells can control growth of mHsp70-positive squamous cell 
carcinomas and thus serum levels of Hsp70 are lower. In case 
of adeno NSCLC, no correlation of the percentage of CD94+/
CD69+ NK cells and serum Hsp70 levels were observed. This 
finding might be attributed to the fact that adenocarcinomas are 
less immunogenic.
Previously, it has been demonstrated that the cell surface 
density of the C-type lectin receptor CD94 was up-regulated on 
NK cells after stimulation with Hsp70-peptide TKD (aa450–463) and 
low-dose IL-2 (17). Apart from Hsp70, it is known that CD94 
interacts with non-classical HLA-E molecules (37), and serves 
either as an activating or inhibitory receptor depending on the 
NKG2C or NKG2A co-receptor (38). In Hsp70 membrane-
positive SCCHN patients, even 2 years after surgery and radiation 
therapy, the expression density of CD94 and NKG2D on NK cells 
was found to be significantly up-regulated (31). An increased 
expression of CD69 on NK cells is associated with an increased 
cytotoxic activity, proliferation, TNF-α production and the induc-
tion of further activation markers, such as CD25 and ICAM-1 
(39). Our present data indicate that an increased percentage of 
CD69 and CD94 positive NK cells is only present in the blood 
of patients with squamous cell but not of adeno NSCLC patients 
and a significant association of the CD94 expression with serum 
Hsp70 could be also only detected in the group of squamous cell 
NSCLC patients (Figures 5A,B).
According to the diversity of their gene expression patterns, 
adenocarcinoma can be divided into subgroups with different 
outcome in overall survival (40). In squamous cell carcinoma 
of the lung, a reinforcement of the innate immune response by 
danger signals, such as circulating Hsp70, might be favorable. 
NK cells are not only able to detect “missing self ” on malignant 
cells (41), but also can recognize membrane Hsp70 if expressed 
in a tumor-specific manner (42). Experimental mouse models 
indicate that the development of tumor-specific CD8+ cytotoxic 
T cell responses is highly dependent on the NK cell-mediated 
elimination of tumor cells (43, 44) through the secretion of 
IFN-γ. Also macrophages and dendritic cells are activated by 
IFN-γ and TNF. An 11-year follow-up epidemiologic survey has 
shown that the paucity of activated NK cells was associated with 
an increased risk to develop cancer (45). Taken together our data 
indicate that NK cells as the first line of defense might play a 
major role in the control of squamous cell NSCLC. The danger 
molecule Hsp70 in the presence of pro-inflammatory cytokines, 
such as IL-2, might support the immune system to reinforce 
immunity against cancer.
cOnclUsiOn
We could show that Hsp70 detected by the lipHsp70 ELISA can 
serve as a tumor biomarker in liquid biopsies of patients with 
squamous cell and adeno NSCLC. Due to the fact that vesicular, 
lipid-bound Hsp70 predominantly originates from viable tumor 
cells, a correlation of serum Hsp70 levels with GTV was found. 
This finding is in accordance to the result that changes in tumor 
volume during radiotherapy in NSCLC patients have potential 
prognostic and predictive value (46, 47).
Compared to healthy individuals, NSCLC patients have 
decreased lymphocyte counts in general. However, a com-
parison of lymphocyte subpopulations in NSCLC patients with 
different histology revealed elevated percentages of CD69+/
CD94+ NK cells in squamous cell but not adeno NSCLC 
patients. This might provide a hint that squamous cell NSCLC 
is more immunogenic than adeno NSCLC. High serum Hsp70 
levels are associated with a larger GTV and lower percentage 
of CD69+/CD94+ NK cells. This might indicate that activated 
NK cells might be able to control growth of mHsp70-positive 
tumors in squamous cell NSCLC patients. If tumor escape 
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